Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Eli Lilly Commits $50M to UNICEF USA Alliance Targeting Non-Communicable Disease Prevention in Children Across 21 LMICs

Fineline Cube May 15, 2026
Company Deals

TenNor Therapeutics Raises $71M in Hong Kong IPO – Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections

Fineline Cube May 14, 2026
Company Deals Drug

Fosun Pharma Secures Global Rights to AriBio’s Alzheimer’s Drug AR1001 in $240M Deal – PDE-5 Inhibitor Shows Promise in Phase III

Fineline Cube May 14, 2026
Company Deals

Merck & Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform

Fineline Cube May 14, 2026
Company Deals

Shanghai Immunocan Biotech Secures RMB 250M Series A Led by Vivo Capital to Advance Gene-Edited Antibody Discovery Platforms

Fineline Cube May 13, 2026
Policy / Regulatory

China’s CDE Reports Record Drug Review Activity in 2025 – Breakthrough Therapy Designations Surge 11% as Regulatory Filings Hit 20,149

Fineline Cube May 14, 2026
Company Drug

Chipscreen Biosciences Secures Macao Market Approval for Bilessglu (Chiglitazar), Novel PPAR Pan-Agonist for Type 2 Diabetes

Fineline Cube May 15, 2026
Company Drug

Biogen Reports Positive Phase II CELIA Results for Diranersen, First-in-Class Tau-Targeting ASO Therapy in Early Alzheimer’s Disease

Fineline Cube May 15, 2026
Company Digital

Alibaba Health’s 2022 Financial Report Shows Revenue Growth, Net Loss

Fineline Cube Jul 6, 2022

China-based Alibaba Health Information Technology Ltd (HKG: 0241) released its 2022 financial report (for the...

Company Policy / Regulatory

Wuxi Biologics Set to Be Removed from US Restricted Trade List

Fineline Cube Jul 6, 2022

Wuxi Biologics (HKG: 2269) is reportedly on the verge of being removed from a US...

Policy / Regulatory R&D

CDE Releases 60th Batch of Chemical Generic Reference Preparations

Fineline Cube Jul 6, 2022

The Center for Drug Evaluation (CDE) has released the 60th batch of chemical generic reference...

Company Deals

Beijing Tianshi Tongda Raises RMB 140M for Autoimmune Disease Therapies

Fineline Cube Jul 5, 2022

China-based Beijing Tianshi Tongda Pharmaceuticals Technology Co., Ltd has reportedly raised RMB 140 million (USD...

Company Deals

Wuhan YZY Biopharma Raises RMB 200M for Bispecific Antibodies and COVID-19 Vaccine Development

Fineline Cube Jul 5, 2022

China-based Wuhan YZY Biopharma Co., Ltd has reportedly raised RMB 200 million (USD 29.8 million)...

Company Deals

Shandong Xinhua Pharmaceutical Inks Tech Transfer Deal for LXH-2201 with IMM

Fineline Cube Jul 5, 2022

China-based Shandong Xinhua Pharmaceutical Co., Ltd (HKG: 0719) has signed a technology transfer agreement with...

Drug

Shionogi Files NDA for S-217622 COVID-19 Antiviral Drug in China

Fineline Cube Jul 5, 2022

Japan-based Shionogi & Co., Ltd has submitted a New Drug Application (NDA) to the National...

Company Drug

InnoCare Pharma’s ICP-490 Receives NMPA Approval for Hematological Malignancies

Fineline Cube Jul 5, 2022

Beijing InnoCare Pharma (HKG: 9969) announced that it has received clinical trial approval from the...

Company Drug

Hrain Biotech and Novartis Receive Breakthrough Therapy Designations for CAR-T and Zolgensma

Fineline Cube Jul 5, 2022

The Center for Drug Evaluation (CDE) website indicates that Hrain Biotechnology Co., Ltd’s BCMA –...

Company Deals

Techbank Medical Closes RMB 100M Series A to Build Global Innovation Platform

Fineline Cube Jul 5, 2022

Shanghai Techbank Medical Technology Co., Ltd, a cardiovascular device maker, has reportedly closed its Series...

Company Deals

PackGene and Genemagic Partner on AAV Production and CDMO Services

Fineline Cube Jul 5, 2022

China-based PackGene LLC has entered into a partnership with compatriot firm Genemagic Biosciences Co., Ltd....

Company Drug

PersonGen BioTherapeutics’ TAA06 Receives Clinical Trial Approval for B7-H3 CAR-T Therapy

Fineline Cube Jul 5, 2022

The Center for Drug Evaluation (CDE) website indicates that PersonGen BioTherapeutics (Suzhou) Co., Ltd’s TAA06,...

Company Drug

Akeso Biopharma’s Cadonilimab Achieves National Delivery in China

Fineline Cube Jul 5, 2022

China-based biotech Akeso Biopharma (HKG: 9926) announced the national delivery of its cadonilimab (AK104), marking...

Company Drug

Sobi’s Anakinra (Kineret) Prioritized for Review in China for FMF Treatment

Fineline Cube Jul 5, 2022

The Center for Drug Evaluation (CDE) website indicates that Swedish Orphan Biovitrum AB’s (Sobi; BMV:...

Company Drug

Arctic Vision Enrolls First Patient in ARVN003 Phase III Trial for Presbyopia

Fineline Cube Jul 5, 2022

China-based ophthalmic therapies developer Arctic Vision announced the first patient enrollment in a Phase III...

Policy / Regulatory

Guangdong Releases 2022 Non-Immunization Vaccine Catalog (7th Batch)

Fineline Cube Jul 5, 2022

The Guangdong Provincial Center for Disease Control and Prevention and Guangdong Medicine Exchange jointly released...

Company

WuXi Biologics’ MFG14 Facility Approved for Microbial Product Manufacturing

Fineline Cube Jul 5, 2022

China-based Contract Research, Development and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) announced that its...

Company Drug

JW Therapeutics Initiates Phase I Study of JWATM204 for Hepatocellular Carcinoma

Fineline Cube Jul 5, 2022

China-based JW Therapeutics (HKG: 2126) announced the initiation of a Phase I clinical study for...

Company Deals

GenScript Biotech’s ProBio Subsidiary Receives USD 37.25M Investment from Zhenjiang Gaoxin

Fineline Cube Jul 4, 2022

Hong Kong-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) announced that Zhenjiang Gaoxin...

Company Deals

Zhiyi Bio Raises RMB 100M in Series B++ Round for LBP Pipeline Development

Fineline Cube Jul 4, 2022

China-based leading live biotherapeutics (LBP) company Guangzhou Zhiyi Biotechnology Co., Ltd has recently raised RMB...

Posts pagination

1 … 654 655 656 … 666

Recent updates

  • Chipscreen Biosciences Secures Macao Market Approval for Bilessglu (Chiglitazar), Novel PPAR Pan-Agonist for Type 2 Diabetes
  • Biogen Reports Positive Phase II CELIA Results for Diranersen, First-in-Class Tau-Targeting ASO Therapy in Early Alzheimer’s Disease
  • Hengrui Pharmaceuticals Secures NMPA Clinical Approval for RSS0393 Latex in Atopic Dermatitis Treatment
  • Eli Lilly Commits $50M to UNICEF USA Alliance Targeting Non-Communicable Disease Prevention in Children Across 21 LMICs
  • Sichuan Biokin Receives NMPA Go-Ahead for SI-B036 Bispecific Antibody Clinical Study in Advanced Solid Tumors
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Chipscreen Biosciences Secures Macao Market Approval for Bilessglu (Chiglitazar), Novel PPAR Pan-Agonist for Type 2 Diabetes

Company Drug

Biogen Reports Positive Phase II CELIA Results for Diranersen, First-in-Class Tau-Targeting ASO Therapy in Early Alzheimer’s Disease

Company Drug

Hengrui Pharmaceuticals Secures NMPA Clinical Approval for RSS0393 Latex in Atopic Dermatitis Treatment

Company Deals

Eli Lilly Commits $50M to UNICEF USA Alliance Targeting Non-Communicable Disease Prevention in Children Across 21 LMICs

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.